- 16 to 3 that if approved, ARYMO ER should be labeled as an abuse-deterrent product by the oral route of abuse;
- 18 to 1 that if approved, ARYMO ER should be labeled as an abuse-deterrent product by the nasal route of abuse; and
- 18 to 1 that if approved, ARYMO ER should be labeled as an abuse-deterrent product by the intravenous route of abuse.
Catalyst
Slingshot members are tracking this event:
Egalet Announces FDA Advisory Committees Recommend Approval of Abuse-Deterrent ARYMO ER (Morphine Sulfate) and Reports Second Quarter 2016 Financial Results
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| EGLT |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 04, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Arymo Er, Morphine Sulfate
